Vedana Therapeutics exits stealth with $46M Series A to develop anti-PACAP and bispecific PACAP/CGRP treatments for migraine prevention.
From L-R: executive chair Rob Lenz, CSO Leon Garcia, CEO Anurag Agarwal and CMO Ernesto Aycardi (courtesy Vedana Therapeutics)
June 17, 2026 05:00 AM EDT
FinancingStartups
Migraine biotech makes its debut with $46M to advance preclinical pipeline
Ayisha Sharma
A new Westlake-backed biotech takes aim at migraines
Monoclonal antibody lowers migraine days in adults with prior preventive treatment failure
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
Biogen adds more immune drugs in $1B buyout of secretive startup Raythera
Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup
Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies,…
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat…
A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but…
Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired…
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand…
